William Chin to lead PhRMA science & regulatory affairs
This article was originally published in Scrip
Executive Summary
The Pharmaceutical Research and Manufacturers of America (PhRMA) has named Dr William Chin executive vice-president of science and regulatory affairs, effective 1 July 2013. Currently, Dr Chin is the executive dean for research at Harvard Medical School. At PhRMA, he will oversee the organization's scientific and regulatory affairs portfolio, including implementation of the Prescription Drug User Fee Act (PDUFA), clinical trials, and drug discovery and research collaboration. He will report to PhRMA president and CEO John Castellani and will also become a member of the PhRMA management committee.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.